Skip to content

PHARMACYTE BIOTECH, INC.: 10-Q filed 2019-12-23

What PHARMACYTE BIOTECH, INC. reported in its quarterly report filed 2019-12-23 (fiscal Q2 2020): 28 published measures, 80 facts as tagged in accession 0001683168-19-004051.

This filing

Form
10-Q (quarterly report)
Filed
2019-12-23
Fiscal period
fiscal Q2 2020
Accession
0001683168-19-004051 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PHARMACYTE BIOTECH, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-10-315,338,332USD
At 2019-04-305,782,396USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2019-10-31803,855USD
At 2019-04-30742,851USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-10-314,534,477USD
At 2019-07-314,999,475USD
At 2019-04-305,039,545USD
At 2018-10-315,404,204USD
At 2018-07-316,198,148USD
At 2018-04-305,768,689USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-08-01 to 2019-10-31-1,067,122USD92
2019-05-01 to 2019-10-31-2,201,197USD184
2019-05-01 to 2019-07-31-1,134,075USD92
2018-08-01 to 2018-10-31-1,036,574USD92
2018-05-01 to 2018-10-31-2,251,937USD184
2018-05-01 to 2018-07-31-1,215,363USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-05-01 to 2019-10-31-1,346,765USD184
2018-05-01 to 2018-10-31-1,540,050USD184

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2019-08-01 to 2019-10-310USD92
2019-05-01 to 2019-10-310USD184
2018-08-01 to 2018-10-310USD92
2018-05-01 to 2018-10-310USD184

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-05-01 to 2019-10-31883,501USD184
2018-05-01 to 2018-10-311,395,000USD184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2019-05-01 to 2019-10-310USD184
2018-05-01 to 2018-10-310USD184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-10-31-102,232,568USD
At 2019-04-30-100,031,371USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2019-08-01 to 2019-10-311,325,086,933shares92
2019-05-01 to 2019-10-311,267,696,383shares184
2018-08-01 to 2018-10-311,080,708,112shares92
2018-05-01 to 2018-10-311,063,602,271shares184

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2019-08-01 to 2019-10-311,325,086,933shares92
2019-05-01 to 2019-10-311,267,696,383shares184
2018-08-01 to 2018-10-311,080,708,112shares92
2018-05-01 to 2018-10-311,063,602,271shares184

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-05-01 to 2019-10-31209,453USD184
2018-05-01 to 2018-10-31184,140USD184

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-08-01 to 2019-10-31-1,067,122USD92
2019-05-01 to 2019-10-31-2,201,197USD184
2018-08-01 to 2018-10-31-1,036,574USD92
2018-05-01 to 2018-10-31-2,251,937USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-10-31209,340USD
At 2019-04-30653,404USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-10-31803,855USD
At 2019-04-30742,851USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2019-10-31164,582USD
At 2019-04-30121,885USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-08-01 to 2019-10-311,067,122USD92
2019-05-01 to 2019-10-312,201,197USD184
2018-08-01 to 2018-10-311,036,574USD92
2018-05-01 to 2018-10-312,251,937USD184

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-08-01 to 2019-10-3117,940USD92
2019-05-01 to 2019-10-3190,270USD184
2018-08-01 to 2018-10-31115,101USD92
2018-05-01 to 2018-10-31382,895USD184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-10-311,331,871,172shares
At 2019-04-301,186,004,505shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2019-10-31106,654,628USD
At 2019-04-30104,966,158USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2019-10-31-20,770USD
At 2019-04-30-13,842USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2019-10-317,372USD
At 2019-04-307,372USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2019-10-31639,273USD
At 2019-04-30620,966USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2019-10-31164,279USD
At 2019-04-30138,151USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2019-08-01 to 2019-10-31-1,067,188USD92
2019-05-01 to 2019-10-31-2,208,125USD184
2018-08-01 to 2018-10-31-1,042,632USD92
2018-05-01 to 2018-10-31-2,259,268USD184

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-08-01 to 2019-10-31404,728USD92
2019-05-01 to 2019-10-31827,480USD184
2018-08-01 to 2018-10-31415,152USD92
2018-05-01 to 2018-10-31716,765USD184

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2019-05-01 to 2019-10-31883,500USD184
2018-05-01 to 2018-10-311,395,000USD184

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2019-05-01 to 2019-10-3142,697USD184
2018-05-01 to 2018-10-31-3,981USD184

Inspect the source

Entity
PHARMACYTE BIOTECH, INC. / CIK 0001157075
Captured
2026-09-20T07:42:36.237Z
SEC response SHA-256
8f9ad1662a11f3cb167c6975b558c6cce5e582ddebd7699a946a7cffe2a40413

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001157075.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))